Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05301842 · ClinicalTrials.gov registry record · Phase 3
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
A Phase 3 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 760
- Enrollment target
- 20
- Study locations
NCT05301842 is a Phase 3 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 760 participants, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (202% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT05301842, a Phase 3 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 760 participants
- Enrollment target
- 20
- Study locations
Study Summary
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
Conditions Studied
Interventions
- DRUG Lenvatinib
- DRUG Durvalumab
- DRUG Tremelimumab
- PROCEDURE Transarterial Chemoembolization (TACE)
Study Locations (20)
Other
- Research Site - Brussels
- Research Site - Ghent
- Research Site - Barretos
- Research Site - Brasília
- Research Site - Niterói
- Research Site - Porto Alegre
- Research Site - Rio de Janeiro
- Research Site - Santa Maria
Alabama
- Research Site - Birmingham
- Research Site - Mobile
New York
- Research Site - Commack
- Research Site - New York
Texas
- Research Site - Dallas
- Research Site - Houston
Arizona
- Research Site - Yuma
California
- Research Site - Glendale
Georgia
- Research Site - Atlanta
Maryland
- Research Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 760 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2027-02-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05301842
The ClinicalTrials.gov registry entry for NCT05301842 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 760 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 252-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (202% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Lenvatinib is the first listed.
NCT05301842 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Alabama, New York.
Frequently Asked Questions
What is clinical trial NCT05301842 about?
NCT05301842 is a clinical study titled "Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC". A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
What is the current status of trial NCT05301842?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 760 participants. The study started on 2022-03-28. Estimated completion is 2027-02-26.
What conditions does trial NCT05301842 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05301842?
The interventions under investigation include: Lenvatinib (DRUG), Durvalumab (DRUG), Tremelimumab (DRUG), Transarterial Chemoembolization (TACE) (PROCEDURE).
Who is sponsoring clinical trial NCT05301842?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05301842 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.